Precision Optics Corporation Inc

Precision Optics Corporation Inc(POCI)股票分析

$4.370

-0.079 (-1.80%)收盘时

Loading chart…
High
4.625
Open
4.565
VWAP
4.45
Vol
82.49K
Mkt Cap
35.15M
Low
4.360
Amount
367.20K
EV/EBITDA, TTM
3,302.11

Precision Optics Corporation, Inc. is a developer and manufacturer of optical instruments. The Company’s segments include medical devices and advanced defense/aerospace products. Its optical and imaging technology, custom designs, manufacturing capabilities, and engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using complementary metal-oxide-semiconductor (CMOS) sensor technology, some designed and manufactured for single-use, as well as other custom imaging and illumination products for our customers’ use in minimally invasive surgical procedures. It designs and manufactures precision endoscopes and microprecision lenses, assemblies and complete medical devices to meet the surgical community’s demand for imaging systems for minimally invasive surgery. Its technologies serve defense / aerospace markets, including applications supporting satellite network communications.

www.poci.com

AI analysis of Precision Optics Corporation Inc (POCI)

buy

Precision Optics Corporation Inc (POCI) is a good buy right now due to its recent strong revenue growth of 107.1% year-over-year, with Q3 revenue reaching $8.7 million, and an upward revision of fiscal year 2026 revenue guidance to $29-$31 million. The current price of $4.40 is above the Fibonacci support level of $4.204, indicating potential for upward movement. However, the main risk is the negative net income of -$108,283 in Q3 2026, which highlights ongoing profitability challenges.

估值指标

The current forward P/E ratio for Precision Optics Corporation Inc (POCI) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
264.76
Current EV/EBITDA
3302.11
高估
1228.62
低估
-699.11

Forward P/S

Strongly Overvalued
5Y Average P/S
0.11
Current P/S
1.39
高估
0.52
低估
-0.29

Alphio AI Price Scenarios for POCI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%POCI

$4.83

情景价格

B

Base

Base · 50%POCI

$4.56

情景价格

B

Bear

Bear · 25%POCI

$3.87

情景价格

事件时间线

2026-03-27 (ET)

07:50:00

Lucid Capital Offering Priced Below Last Closing Price of $4.21

2026-03-26 (ET)

16:10:00

Precision Optics Corporation Launches Underwritten Public Offering

2025-11-11 (ET)

09:05:48

Precision Optics reveals partnership for product development

2025-11-07 (ET)

09:01:55

Precision Optics Secures Order for Development of AR Sub-Systems

2025-06-05 (ET)

09:03:32

Precision Optics expands facilities to meet growing backlog

资讯

POCI FAQ — answered by Alphio AI

Precision Optics Corporation, Inc. is a developer and manufacturer of optical instruments. The Company’s segments include medical devices and advanced defense/aerospace products. Its optical and imaging technology, custom designs, manufacturing capabilities, and engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using complementary metal-oxide-semiconductor (CMOS) sensor technology, some designed and manufactured for single-use, as well as other custom imaging and illumination products for our customers’ use in minimally invasive surgical procedures. It designs and manufactures precision endoscopes and microprecision lenses, assemblies and complete medical devices to meet the surgical community’s demand for imaging systems for minimally invasive surgery. Its technologies serve defense / aerospace markets, including applications supporting satellite network communications. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Precision Optics Corporation Inc (POCI) is a good buy right now due to its recent strong revenue growth of 107.1% year-over-year, with Q3 revenue reaching $8.7 million, and an upward revision of fiscal year 2026 revenue guidance to $29-$31 million. The current price of $4.40 is above the Fibonacci support level of $4.204, indicating potential for upward movement. However, the main risk is the negative net income of -$108,283 in Q3 2026, which highlights ongoing profitability challenges.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始